Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344760 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00344760 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants.
The verdict
NCT00344760, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower number of minority variant HIV-1 strains.
Interventions
- DRUG Enfuvirtide
- DRUG Efavirenz, lamivudine, and tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344760
The ClinicalTrials.gov registry entry for NCT00344760 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enfuvirtide is the first listed.
NCT00344760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00344760 about?
NCT00344760 is a clinical study titled "A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy". We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower number of minority variant HIV-1 strains.
What is the current status of trial NCT00344760?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2005-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00344760?
The interventions under investigation include: Enfuvirtide (DRUG), Efavirenz, lamivudine, and tenofovir (DRUG).
Who is sponsoring clinical trial NCT00344760?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.